Advertisement
The study, led by Dr. Jon Myers of Stanford University and the VA PaloAlto Health Care System, used the NICOM to measure the cardiac output of 36patients. Results showed that the NICOM accurately measured cardiac output.This is the first time that the NICOM was used in a study duringcardiopulmonary exercise on heart failure patients.
Advertisement
Dr. Myers concluded, "NICOM provided accurate measurements of cardiacoutput and thoracic fluid during cardiopulmonary exercise. The possibility ofusing a non-invasive, accurate tool to measure cardiac output may provideclinicians with an important diagnostic tool that can contribute tooptimization of CHF treatment and provide an early indication of diseaseescalation."
The NICOM(TM) Cardiac Output Monitor, developed by Cheetah Medical, is aportable system that utilizes the proprietary BIOREACTANCE(TM) technology tomeasure cardiac output in virtually any clinical setting. Cheetah considersBIOREACTANCE to be a superior modality to measure cardiac output, especiallyin clinical settings where continuous monitoring of cardiac output isimperative, and in clinical environments such as intensive care units,emergency departments and during stress tests, where there is significantelectrical noise and patient movement.
Cheetah's BIOREACTANCE(TM) technology has been validated in the UnitedStates and Europe on hundreds of hemodynamically challenged patients in avariety of clinical settings, in the presence of significant environmentalfactors.
Laura Rector, General Manager of Cheetah Medical in the United Statesstated, "This study is important because, until the NICOM System, there hasnot been a technology as practical and simple, that is available toclinicians to accurately and easily provide exercise cardiac output. TheNICOM System is a robust diagnostic tool for measuring cardiac output. Thepatented BIOREACTANCE technology opens opportunities for clinicians toimprove patient care based on real-time accurate cardiac output measurements."
Ms. Rector continued, "We have now established our US Sales and MarketingOrganization and we are excited about starting sales in the US Market. Basedon the initial market reaction, there is clearly a great, untapped need forCheetah's unique and proprietary technology."
About the BIOREACTANCE(TM) Technology
The Cheetah family of NICOM Cardiac Output Monitors implements the uniqueand proprietary BIOREACTANCE(TM) technology. BIOREACTANCE is a noveltechnology platform which analyzes changes in amplitude as well as frequencyof electrical impulses as they traverse the chest. These changes are analyzedby software programming to provide a continuous, highly accurate and stable,non-invasive measurement of cardiac output and other cardiac parameters.
About the Company
Cheetah Medical is based in Tel Aviv, Israel and Indianapolis, Indiana.The company is establishing NICOM(TM) as a frontline tool to monitor cardiacfunction in inpatient and outpatient areas of high unmet need. Importantly,this unique and proprietary technology has been proven to provide accurateand reliable measurements of cardiac output, even during patient movement andacross a variety of body types. These features enable the device to be usedin several important clinical applications, including intensive care,anesthesia and peri-operative settings, step down, emergency room, dialysisclinic, cardiac care unit, ECO(TM) (Exercise CO testing), CRT-pacemakeroptimization, thoracic fluid content (TFC) for acute and chronic heartfailure management, home Holter monitoring of cardiac rhythm, thoracic fluidcontent and ca
